Covid-19: Pfizer laboratory announces that its vaccine is 90% effective
Compartir :
The Pfizer and BioNTech laboratories announced this morning that the effectiveness of their vaccine against Covid-19 would be around 90%. This candidate vaccine is currently in phase 3 of the clinical trial, the last step before an application for approval for commercialization.
"Today is a great day for science and humanity. The first set of results from our phase 3 trial provides evidence of the ability of our vaccine to prevent Covid-19," said Dr. Albert Bourla, President and CEO Pfizer executive, in a statement issued on Monday, November 9, 2020.
In fact, the laboratories of Pfizer and BioNTech have announced that their vaccine candidate (BNT162b2) was at least 90% effective in preventing SARS-CoV-2 coronavirus infections. This news gives some hope to the many countries currently facing a second wave of pollution.
The efficacy of the vaccine was measured in a first interim analysis of the phase 3 clinical trial of the vaccine. At the moment, 94 positive volunteers for Covid-19 have been studied. The researchers compared the number of participants infected with the new coronavirus in the group that received the vaccine and in the group that received placebo:
"Our conclusions indicate a vaccine efficacy rate higher than 90%, 7 days after the second dose. This means that protection is obtained 28 days after the start of vaccination, which consists of a 2-dose schedule" , specify. the press release.
"More than eight months after the onset of the worst pandemic in more than a century, we believe this step represents a significant advance for the world in our battle against Covid-19," said Dr. Albert Bourla.
Up to 50 million doses available in 2020
The phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, of whom 38,955 have received a second dose of the candidate vaccine as of November 8, 2020. Preliminary data is expected to be released. publish and discuss shortly with regulatory authorities around the world.
The study will also evaluate the potential of the candidate vaccine to provide protection against Covid-19 in people who have previously been exposed to SARS-CoV-2, as well as the vaccines prevention against severe forms of Covid-19.
According to projections, Pfizer and BioNTech said they plan to deliver up to 50 million doses of vaccine globally in 2020 and up to 1.3 billion doses in 2021.
There are currently 10 vaccines in phase 3 clinical trials
As of November 9, according to the World Health Organization (WHO), 10 vaccine clinical trials are currently in phase 3 worldwide, including that of Moderna, Novavax, several Chinese state laboratories, and Britains AstraZeneca. Pfizer and BioNTech are the first to publish the interim results of their trial.
Compartir :